Sex-Related Outcomes in Elderly Patients Presenting With Non–ST-Segment Elevation Acute Coronary Syndrome
Marco De CarloNuccia MoriciStefano SavonittoVincenzo GrassiaPaolo SbarzagliaPaola TamburriniClaudio CavalliniMarcello GalvaniPaolo OrtolaniStefano De ServiAnna Sonia Petronio
39
Citation
13
Reference
10
Related Paper
Citation Trend
Keywords:
Clinical endpoint
Stroke
ST elevation
The identification of acute coronary syndrome continues to challenge even experienced clinicians. Emergency physicians have the responsibility to identify, treat and admit those patients with true acute coronary syndrome to the appropriate units. This article described a case of acute coronary syndrome that developed in the observation ward, with discussion on some recent reviews of standard electrocardiogram analysis. It is very important to point out that controversy over the measurement of ST elevation exists which may adversely affect patient management.
ST elevation
Elevation (ballistics)
Cite
Citations (1)
The aim of this study was to better delineate the characteristics, treatments and outcomes of patients with acute coronary syndromes in Emilia Romagna, a region of Italy, with 4 million inhabitants.From January 10 to March 12, 2000, we performed a prospective survey (24/27 hospitals of the region) on 1074 consecutive patients with a discharge diagnosis of acute coronary syndrome.Based on the initial electrocardiogram, patients were classified as having an ST-elevation acute coronary syndrome in 41% of cases, a non-ST-elevation acute coronary syndrome in 54%, and an acute coronary syndrome with an undetermined electrocardiographic pattern in 5%. The discharge diagnosis was Q wave myocardial infarction in 43%, non-Q wave myocardial infarction in 26%, and unstable angina in 31% of patients. The use of antiplatelet, beta-blockers, ACE-inhibitors, and antithrombin agents for patients with ST-elevation acute coronary syndromes were 96, 62, 56, and 93%, respectively, with corresponding rates of 93, 63, 53, and 87% for non-ST-elevation acute coronary syndromes. During the initial admission, coronary angiography, percutaneous coronary intervention, and coronary bypass surgery were performed in 31, 15, and 1% of ST-elevation acute coronary syndrome patients, respectively, with corresponding rates of 43, 15, and 5% for non-ST-elevation acute coronary syndromes. Among patients with ST-elevation acute coronary syndromes, 61% received a reperfusion treatment; 58% coronary thrombolysis, and 3% primary percutaneous coronary intervention. The in-hospital mortality of patients with ST-elevation acute coronary syndromes was 10%, of patients with non-ST-elevation acute coronary syndromes 3%, and of patients with underdetermined electrocardiographic acute coronary syndromes 8%. At 6 months, the mortality rate increased to 16, 8, and 18%, respectively.Our data show the use of evidence-based pharmacological treatments in this population. This is associated with clinical outcomes which favorably compare with those observed in clinical trials. However, there is still room for improvement in the implementation of the invasive treatment.
ST elevation
Unstable angina
Cite
Citations (2)
The aim was to study early outcomes in patients with suspected acute coronary syndrome without ST elevation who were transported by emergency to the vascular center. Material and Methods . We studied medical records from 396 patients with suspected acute coronary syndrome without ST elevation. A telephone survey of patients or their relatives was conducted within two months after the emergency call. Results . In-hospital diagnosis of acute coronary syndrome was confirmed only in 30.6% of patients with suspected acute coronary syndrome without ST elevation admitted to the vascular center. Cardiologists in the vascular center were ruling out diagnosis of acute coronary syndrome without ST elevation based on data of clinical examination and electrocardiography. During the following two months, 6.4% of the patients with ruled out diagnosis of acute coronary syndrome called emergency again; 2% of the patients were admitted with acute coronary syndrome to the vascular center; and 2.4% of the patients died at home. Conclusion . In real clinical practice, the assessment of myocardial necrosis biomarkers has been used not enough in cases of suspected acute coronary syndrome without ST elevation.
ST elevation
Cite
Citations (0)
Complete revascularization in ST elevation myocardial infarction (STEMI) patients with multivessel disease has resulted in reduction in composite clinical endpoints in medium sized trials. Only one trial showed an effect on hard clinical endpoints, but the revascularization procedure was guided by angiographic evaluation of stenosis severity. Consequently, it is not clear how Fractional Flow Reserve (FFR)-guided percutaneous coronary intervention (PCI) affects hard clinical endpoints in STEMI. The Ffr-gUidance for compLete non-cuLprit REVASCularization (FULL REVASC) – is a pragmatic, multicenter, international, registry-based randomized clinical trial designed to evaluate whether a strategy of FFR-guided complete revascularization of non-culprit lesions, reduces the combined primary endpoint of total mortality, non-fatal MI and unplanned revascularization. 1,545 patients were randomized to receive FFR-guided PCI during the index hospitalization or initial conservative management of non-culprit lesions. We found that in angiographically severe non-culprit lesions of 90-99% severity, 1 in 5 of these lesions were re-classified as non-flow limiting by FFR. Considering lesions of intermediate severity (70%-89%), half were re-classified as non-flow limiting by FFR. The study is event driven for an estimated follow-up of at least 2.75 years to detect a 9.9%/year>7.425%/year difference (HR = 0.74 at 80% power (α = .05)) for the combined primary endpoint. This large randomized clinical trial is designed and powered to evaluate the effect of complete revascularization with FFR-guided PCI during index hospitalization on total mortality, non-fatal MI and unplanned revascularization following primary PCI in STEMI patients with multivessel disease. Enrollment completed in September 2019 and follow-up is ongoing.
Culprit
Fractional Flow Reserve
Clinical endpoint
Cite
Citations (8)
Objective: Researching the relationship between C-reactive protein and non- ST elevation acute coronary syndrome and its clinical meaning. Methods: Measuring C-reactive protein value of 62 patients with non- ST elevation acute coronary syndrome and 80 stable angina in the hospital from Jan 2000 to Jan 2005, observing the difference of two different type coronary heart disease. Results: There was obvious difference between non-ST elevation acute coronary syndrome and stable angina. Conclusion: C-reactive protein and non- ST elevation acute coronary syndrome have obvious relativity, can be the basis that discriminates non- ST elevation acute coronary syndrome for stable angina on clinic.
ST elevation
Unstable angina
Elevation (ballistics)
Cite
Citations (0)
Background: Complete revascularization is the standard treatment for patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease. The Functional Assessment in Elderly MI Patients with Multivessel Disease (FIRE) trial confirmed the benefit of complete revascularization in a population of older patients, but the follow-up is limited to 1 year. Therefore, the long-term benefit ( > 1-year) of this strategy in older patients is debated. To address this, an individual patient data meta-analysis was conducted in STEMI patients aged 75 years or older enrolled in randomized clinical trials investigating complete vs. culprit-only revascularization strategies. Methods: PubMed, Embase, and the Cochrane database, were systematically searched to identify randomized clinical trials comparing complete vs. culprit-only revascularization. Individual patient-level data were collected from the relevant trials. The primary endpoint was death, myocardial infarction (MI), or ischemia-driven revascularization. The secondary endpoint was cardiovascular death or myocardial infarction. Results: Data from seven RCTs, encompassing 1733 patients (917 randomized to culprit-only and 816 to complete revascularization), were analyzed. The median age was 79 [77-83] years. Females were 595 (34%). Follow-up ranged from a minimum of six months to a maximum of 6.2 years (median 2.5 [1-3.8] years). Complete revascularization reduced the primary endpoint up to four years (HR 0.78, 95%CI 0.63-0.96), but not at the longest available follow-up (HR 0.83, 95%CI 0.69-1.01). Complete revascularization significantly reduced the occurrence of cardiovascular death or MI at the longest available follow-up (HR 0.76, 95%CI 0.58-0.99). This was observed even when censoring the follow-up at each year. Long-term rate of death did not differ between complete and culprit-only revascularization arms. Conclusions: In this individual patient data meta-analysis of older STEMI patients with multivessel disease, complete revascularization reduced the primary endpoint of death, MI or ischemia-driven revascularization up to 4-year. At the longest follow-up, complete revascularization reduced the composite of cardiovascular death or MI, but not the primary endpoint. Clinical Study Registration: PROSPERO CRD42022367898
Clinical endpoint
Culprit
Cite
Citations (4)
The first New Zealand Acute Coronary Syndrome (ACS) national audit of 2002 was a collaborative effort between clinicians and nurses, and demonstrated important limitations to Non ST-elevation ACS patient (NSTEACS) care. A momentum for change was created. Subsequent audits in 2007 and 2012 allow assessment over time.Over 14 days in May 2002, 2007 and 2012, patients with suspected ACS admitted to a hospital in New Zealand were audited. 'Definite' ACS was determined at discharge, after in-hospital investigations; we reviewed NSTEACS patients.From 2002, more patients underwent assessment of left ventricular function (echocardiogram) and coronary angiography. Evidence-based in-hospital medical treatments and revascularisation have also increased over the decade.Over a ten-year period, evidence-based care for patients presenting with a NSTEACS event in New Zealand has improved. However, considerable room remains to optimise management, particularly with development of systems of care to facilitate prompt referral and delivery of angiography in these high-risk individuals.
ST elevation
Acute care
Cite
Citations (1)
ST elevation
Elevation (ballistics)
Cite
Citations (0)
Objective To investigate the relationship between the plasma C -reactive protein and non -ST elevation acute coronary syndrome and its clinical significance.Methods The plasma Creactive protein levels of 112 patients with non -ST elevation acute coronary syndrome and 90 stable angina in the hospital from Feb.2004 to Feb.2010 were detected,the differences of two different type coronary heart disease were observed.Results There was obvious difference between non -ST elevation acute coronary syndrome and stable angina.Conclusions The plasma C - reactive protein and non - ST elevation acute coronary syndrome have obvious correlation,and can be important for discriminating non - ST elevation acute coronary syndrome from stable angina on clinic.
Key words:
Plasma C -reactive protein; Acute coronary syndrome; Stable angina
Unstable angina
ST elevation
Cite
Citations (0)